Brief: Transgene Updates On TG6002 Phase I Data

Transgene SA

12/09/2022 07:06

Sept 12 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE CONFIRMS POTENTIAL OF INTRAVENOUS ROUTE OF ITS
INVIR.IO™ ONCOLYTIC VIRUSES AGAINST SOLID TUMORS WITH TG6002
PHASE I DATA PRESENTED AT ESMO CONGRESS 2022

Source text for Eikon:  ID:nBw38slLDa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))